Drug Trial Radar · NCT06471361
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Aug 27, 2024
Primary completion
Jan 28, 2025
Study completion Feb 3, 2025
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Jun 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effectiveness, safety and tolerability of zilucoplan auto-injector (ZLP-AI) self-administration.
Conditions
- Generalized Myasthenia Gravis
Interventions
ZilucoplanDrug
Zilucoplan will be self-administered subcutaneously by study participants at pre-specified time points.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Effective Self-administrations (SA) of Zilucoplan (ZLP) Using the Zilucoplan-auto-injector (ZLP-AI) From Visit 1 to Visit 8Time frame: From Visit 1 (Day 1) to Visit 8 (Day 14)
Locations
11 sites in 3 countries. Site status is shown where the registry gives one.
Dv0013 50628
New Haven, Connecticut
Dv0013 50634
Tampa, Florida
Dv0013 50648
Columbia, Missouri
Dv0013 50556
Chapel Hill, North Carolina
Dv0013 50635
Columbus, Ohio
Dv0013 50555
Austin, Texas
Dv0013 50636
Greenfield, Wisconsin
Dv0013 40609
Katowice, Poland
Dv0013 40759
Krakow, Poland
Dv0013 40605
Poznan, Poland
Dv0013 40760
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.